

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

April 01, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**April 1, 2013**

**(Date of earliest event reported)**

**LABORATORY CORPORATION OF AMERICA  
HOLDINGS**

**(Exact Name of Registrant as Specified in its Charter)**

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

**DELAWARE**  
(State or other jurisdiction

**1-11353**  
(Commission

**13-3757370**  
(I.R.S. Employer

of Incorporation)

File Number)

Identification No.)

**358 SOUTH MAIN STREET,**

**BURLINGTON, NORTH CAROLINA**  
(Address of principal executive offices)

**27215**  
(Zip Code)

**336-229-1127**  
(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On April 1, 2013, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb Company (NYSE: BMY).

On April 1, 2013, LabCorp also announced the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease (IBD).

Exhibits

99.1 Press Release dated April 1, 2013

99.2 Press Release dated April 1, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings

By: /s/ F. SAMUEL EBERTS III  
F. Samuel Eberts III

Chief Legal Officer and Secretary

April 1, 2013